Quick Answer
Inmune Bio, Inc. reported Operating Income of -$47.38 million for fiscal year 2025.
Inmune Bio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$47.38M | -11.1% |
| 2024 | -$42.63M | -43.4% |
| 2023 | -$29.74M | -14.6% |
| 2022 | -$25.95M | +11.0% |
| 2021 | -$29.15M | -138.4% |
| 2020 | -$12.23M | -57.7% |
| 2019 | -$7.76M | +37.7% |
| 2018 | -$12.44M | -1167.5% |
| 2017 | -$981.5K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.43M | +39.5% | +69.7% |
| June 30, 2025 | -$24.57M | -149.1% | -148.1% |
| March 31, 2025 | -$9.90M | +10.1% | +19.4% |
| September 30, 2024 | -$12.29M | -44.1% | -24.5% |
| June 30, 2024 | -$9.87M | -53.9% | +10.5% |
| March 31, 2024 | -$11.02M | -71.5% | -29.2% |
| September 30, 2023 | -$8.53M | -14.6% | -33.0% |
| June 30, 2023 | -$6.41M | -0.4% | +0.2% |
- Inmune Bio, Inc. showed a decrease of -11.1% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Inmune Bio, Inc.’s operating income has declined by 4727.7% (from -$981.5 thousand to -$47.38 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: